Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
Status:
Completed
Trial end date:
2023-11-14
Target enrollment:
Participant gender:
Summary
This is a single-center, 2-part (Part A and Part B) study in healthy participants. Part A
(Dose Finding) is an open-label, SAD study to identify the dose for Part B. Part B (TQT
Study) is a randomized, double-blind (with respect to aficamten and matching placebo),
positive- and placebo-controlled, single-dose, 3-way crossover study to evaluate the effect
of aficamten administration on QT/QTc interval.